S&P 500   4,449.91 (-0.13%)
DOW   35,023.63 (+0.65%)
QQQ   368.58 (-1.27%)
AAPL   144.19 (-1.86%)
MSFT   294.31 (-1.68%)
FB   348.40 (-1.29%)
GOOGL   2,807.50 (-1.29%)
TSLA   771.90 (-0.32%)
AMZN   3,349.83 (-2.21%)
NVDA   214.43 (-2.89%)
BABA   145.36 (+0.19%)
NIO   34.91 (-1.33%)
CGC   14.14 (+1.65%)
GE   106.08 (+2.20%)
MU   74.45 (+0.54%)
AMD   103.83 (-1.86%)
T   27.47 (+1.25%)
F   14.13 (+2.54%)
ACB   6.04 (+1.51%)
DIS   176.97 (+0.55%)
PFE   43.77 (-0.39%)
BA   228.34 (+3.14%)
BAC   43.32 (+2.80%)
S&P 500   4,449.91 (-0.13%)
DOW   35,023.63 (+0.65%)
QQQ   368.58 (-1.27%)
AAPL   144.19 (-1.86%)
MSFT   294.31 (-1.68%)
FB   348.40 (-1.29%)
GOOGL   2,807.50 (-1.29%)
TSLA   771.90 (-0.32%)
AMZN   3,349.83 (-2.21%)
NVDA   214.43 (-2.89%)
BABA   145.36 (+0.19%)
NIO   34.91 (-1.33%)
CGC   14.14 (+1.65%)
GE   106.08 (+2.20%)
MU   74.45 (+0.54%)
AMD   103.83 (-1.86%)
T   27.47 (+1.25%)
F   14.13 (+2.54%)
ACB   6.04 (+1.51%)
DIS   176.97 (+0.55%)
PFE   43.77 (-0.39%)
BA   228.34 (+3.14%)
BAC   43.32 (+2.80%)
S&P 500   4,449.91 (-0.13%)
DOW   35,023.63 (+0.65%)
QQQ   368.58 (-1.27%)
AAPL   144.19 (-1.86%)
MSFT   294.31 (-1.68%)
FB   348.40 (-1.29%)
GOOGL   2,807.50 (-1.29%)
TSLA   771.90 (-0.32%)
AMZN   3,349.83 (-2.21%)
NVDA   214.43 (-2.89%)
BABA   145.36 (+0.19%)
NIO   34.91 (-1.33%)
CGC   14.14 (+1.65%)
GE   106.08 (+2.20%)
MU   74.45 (+0.54%)
AMD   103.83 (-1.86%)
T   27.47 (+1.25%)
F   14.13 (+2.54%)
ACB   6.04 (+1.51%)
DIS   176.97 (+0.55%)
PFE   43.77 (-0.39%)
BA   228.34 (+3.14%)
BAC   43.32 (+2.80%)
S&P 500   4,449.91 (-0.13%)
DOW   35,023.63 (+0.65%)
QQQ   368.58 (-1.27%)
AAPL   144.19 (-1.86%)
MSFT   294.31 (-1.68%)
FB   348.40 (-1.29%)
GOOGL   2,807.50 (-1.29%)
TSLA   771.90 (-0.32%)
AMZN   3,349.83 (-2.21%)
NVDA   214.43 (-2.89%)
BABA   145.36 (+0.19%)
NIO   34.91 (-1.33%)
CGC   14.14 (+1.65%)
GE   106.08 (+2.20%)
MU   74.45 (+0.54%)
AMD   103.83 (-1.86%)
T   27.47 (+1.25%)
F   14.13 (+2.54%)
ACB   6.04 (+1.51%)
DIS   176.97 (+0.55%)
PFE   43.77 (-0.39%)
BA   228.34 (+3.14%)
BAC   43.32 (+2.80%)
ASX:ZLD

Zelira Therapeutics Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume311,821 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Receive ZLD News and Ratings via Email

Sign-up to receive the latest news and ratings for Zelira Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


About Zelira Therapeutics

Zelira Therapeutics Limited, a bio-pharmaceutical company, engages in the development of cannabinoid-based formulations for the treatment of various medical conditions in Australia. It offers formulations under the HOPE brand in Pennsylvania and licenses in Louisiana, as well as develops Zenivol, a cannabinoid-based medicine for treatment of chronic insomnia. The company is also involved in a human clinical trial program focused on insomnia, autism, and opioid reduction; and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer, as well as the potential for cannabinoid formulations to treat diabetes-associated cognitive decline. It has a strategic partnership with CannPal Pty Ltd; and St Vincent's Hospital on opioid reduction study. The company was formerly known as Zelda Therapeutics Limited and changed its name to Zelira Therapeutics Limited in December 2019. Zelira Therapeutics Limited is based in Perth, Australia.

Headlines

Zelda Therapeutics Limited (ZLDAF)
Zelda Therapeutics Limited (ZLDAF)
May 30, 2021 |  uk.finance.yahoo.com
Zelira Therapeutics Limited (ZLDAF)
Zelira Therapeutics Limited (ZLDAF)
August 19, 2020 |  ca.finance.yahoo.com
Zelira Therapeutics accelerates towards commercialisation in 2020
Zelira Therapeutics accelerates towards commercialisation in 2020
March 21, 2020 |  www.proactiveinvestors.com
Zelira Therapeutics fully enrols cannabis clinical trial
Zelira Therapeutics fully enrols cannabis clinical trial
February 28, 2020 |  www.proactiveinvestors.com.au
Emerald Clinics gets nod for Zeliras opioid sparing clinical trial
Emerald Clinics gets nod for Zelira's opioid sparing clinical trial
February 26, 2020 |  www.proactiveinvestors.com.au
Zelira Therapeutics overseas interest boosts capital raising
Zelira Therapeutics overseas interest boosts capital raising
February 18, 2020 |  www.proactiveinvestors.com.au
Zelira Therapeutics will expand HOPE® distribution to US state of Louisiana
Zelira Therapeutics will expand HOPE® distribution to US state of Louisiana
December 4, 2019 |  www.proactiveinvestors.com.au
See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

0.91 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Zelira Therapeutics (ASX:ZLD) Frequently Asked Questions

What stocks does MarketBeat like better than Zelira Therapeutics?

Wall Street analysts have given Zelira Therapeutics a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Zelira Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How were Zelira Therapeutics' earnings last quarter?

Zelira Therapeutics Limited (ASX:ZLD) posted its earnings results on Friday, February, 22nd. The company reported $0.00 earnings per share (EPS) for the quarter.
View Zelira Therapeutics' earnings history
.

Who are Zelira Therapeutics' key executives?

Zelira Therapeutics' management team includes the following people:
  • Mr. Osagie O. Imasogie, Founder & Chairman (Age 59, Pay $84k)
  • Mr. Harry Karelis B.Sc (Hons), MBA, CFA, F.Fin, FAICD, Co-Founder & Non-Exec. Deputy Chairman (Age 51, Pay $120k)
  • Mr. Jason William Peterson, Co-Founder & Non-Exec. Director
  • Dr. Oludare Odumosu, CEO of USA, MD of USA & Director
  • Mr. Timothy Ryan Slate, Company Sec.
  • Dr. Patty Washer, Clinical Trial Consultant

What other stocks do shareholders of Zelira Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zelira Therapeutics investors own include Saputo (SAP), The Western Union (WU), TransEnterix (TRXC), Intuitive Surgical (ISRG) and Heat Biologics (HTBX).

What is Zelira Therapeutics' stock symbol?

Zelira Therapeutics trades on the ASX under the ticker symbol "ZLD."

How much money does Zelira Therapeutics make?

Zelira Therapeutics has a market capitalization of $0.00 and generates $663,316.00 in revenue each year.

What is Zelira Therapeutics' official website?

The official website for Zelira Therapeutics is www.zeldatherapeutics.com.

How can I contact Zelira Therapeutics?

The company can be reached via phone at 61 8 6558 0886.


This page was last updated on 9/27/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.